Stay updated on Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedRevision: v3.3.3 has been added to the history, and HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed from the page footer. These updates reflect minor metadata changes to the page's revision history.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedRevision: v3.3.2 appears as the site revision tag, replacing v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check54 days agoChange DetectedThe general government funding notice about operating status was removed; otherwise the study record history content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check75 days agoChange DetectedThe two screenshots show the same Record History table with no new version data or changes to core content. Only minor UI/visual adjustments are evident.SummaryDifference0.1%

- Check97 days agoChange DetectedAdded a government-operating-status notice and a version bump to v3.2.0; removed the previous version label v3.1.0.SummaryDifference10%

- Check104 days agoChange DetectedUpdate: version bumped from v3.0.2 to v3.1.0.SummaryDifference0.2%

Stay in the know with updates to Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.